Radiotherapy can be given between or during chemotherapy cycles, rather than sequentially, for women with early breast cancer.
Aflibercept added to FOLFIRI chemotherapy improved PFS and OS in previously treated patients with metastatic colorectal cancer.
T-DM1 extended progression-free survival by 40% in HER2+ metastatic breast cancer and was less toxic, compared with standard therapy.
Panitumumab + chemo improves OS and PFS in patients with metastatic carcinoma of the head and neck that were negative for HPV.
Investigational drug that emits alpha radiation shows significant improvement in overall survival.
Patients with liver metastases from uveal melanoma had improved survival after treatment with percutaneous hepatic perfusion (PHP).
Two studies enhance understanding of risk factors for prostate cancer.